Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma

This study has been completed.
Sponsor:
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT00294632
First received: February 20, 2006
Last updated: February 3, 2016
Last verified: February 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2016
  Primary Completion Date: February 2016 (Final data collection date for primary outcome measure)
No publications provided by M.D. Anderson Cancer Center

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):